Menu

IRIDEX Corporation IRIX

Full chart Compare
Set alert

Price alert · IRIX

All alert types
0.68 USD 0.00 (-0.63%)

Nov 6, 2026, 3:08 PM EST

0.6605 Day range 0.70
0.61 52-week range 1.65
YTD
-40.73%
1 year
-35.65%
Market cap
11.87M
Revenue (ttm)
48.43M
Profit margin
-22.79%
EPS (ttm)
-0.20
Shares out
16.64M
Forward P/E
-5.85
YTD return
-40.73%
1-year return
-35.65%
Volume
20.84K
Avg volume
391.55K
Open
0.69
Previous close
0.68
Day's range
0.6605 – 0.70
52-week range
0.61 – 1.65

6M -0.3543 (-34.40%)

0.60000.80001.00001.2000May 27Jul 2Aug 10Sep 15Oct 200.6757

Key statistics

Enterprise value
28.33M
PEG ratio
0.00
Price / sales
0.54
Price / book
10.00
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-9.90%
Free cash flow
-1.40M
Total cash
3.86M
Total debt
4.91M
Return on equity
-150.28%
Short % of float
1.83%
50-day average
1.65
200-day average
2.14

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
IRIX Revenue — quarterly 12.57M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
IRIX Net income — quarterly -1.27M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
IRIX EPS — quarterly -0.07
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

IRIX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 20240.00-0.12——
Aug 8, 2024Jun 1, 2024-0.12-0.16-0.04-33.33%
May 14, 2024Mar 1, 2024-0.12-0.21-0.09-75.00%
Mar 26, 2024Dec 1, 2023-0.05-0.18-0.13-260.00%
Nov 14, 2023Sep 1, 2023-0.13-0.11+0.02+15.38%
Aug 10, 2023Jun 1, 2023-0.11-0.17-0.06-54.55%

Upgrades / downgrades

IRIX analyst upgrades and downgrades
DateFirmActionFromTo
May 15, 2024StifelmainHoldHold
Aug 26, 2022StifeldownBuyHold
May 12, 2021Roth Capitalmain—Buy
Mar 3, 2021Roth Capitalmain—Buy
Jan 13, 2021Roth Capitalmain—Buy
May 12, 2020Stifelmain—Buy

About IRIDEX Corporation

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
iridex.com

News

Your note

Sign in to keep a note on IRIX — it syncs with the Stock Master app.

Insider holders

IRIX insider holders
InsiderRelationLatest transactionDateShares held
DEVI NANDINIDirectorStock Award(Grant)Jun 13, 202377,159
GROVE ROBERT EARLEDirectorStock Award(Grant)Jun 13, 2023160,103
HUSS BEVERLY ADirectorStock Award(Grant)Jun 13, 202366,739
LUDLUM KENNETH E.DirectorStock Award(Grant)Jun 13, 2023101,711
MERCER PATRICKChief Executive OfficerStock Award(Grant)Nov 6, 2024393,244
SHUDA SCOTT ADirectorStock Award(Grant)Jun 13, 2023108,066

Institution ownership

IRIX institution ownership
Holder% heldSharesValueReported
Paragon Associates & Paragon Associates Ii Joint Venture6.01%1,000,0001.58MSep 29, 2024
Vanguard Group Inc3.37%561,096886.53KSep 29, 2024
AMH Equity Ltd.3.01%501,121791.77KSep 29, 2024
Renaissance Technologies, LLC2.39%397,360627.83KSep 29, 2024
Geode Capital Management, LLC0.79%131,172207.25KSep 29, 2024
ARS Investment Partners, LLC0.68%113,565179.43KSep 29, 2024

Fund ownership

IRIX fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.27%376,944595.57KSep 29, 2024
Vanguard Extended Market Index Fund0.99%164,113259.30KSep 29, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.45%75,000118.50KSep 29, 2024
Fidelity Extended Market Index Fund0.43%71,096112.33KOct 30, 2024
iShares Micro Cap ETF0.20%33,60253.09KOct 30, 2024
Fidelity Series Total Market Index Fund0.10%16,06525.38KOct 30, 2024